Note K - Leases (Tables)

3 Months Ended

Mar. 31, 2025

	*Three months ended March 31,*
Lease Cost	*2025*			*2024*
Finance lease cost:
Amortization of right-of-use assets	$	1		$	12
Total finance lease cost		1			12
Operating lease cost		118			93
Short-term lease cost		47			59
Variable lease cost		—			13
Less: sublease income		(39	)		(39	)
Total lease costs	$	127		$	138

	*Three months ended March 31,*
	*2025*		*2024*
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases		215		123
Operating cash flows from short-term leases		47		59
Operating cash flows from variable lease costs		—		13

Right-of-use assets obtained in exchange for lease liabilities:
Operating leases		1,115		419

	*March 31,*			*December 31,*
	*2025*			*2024*
Finance Leases
Property and equipment, at cost	$	1,031		$	1,031
Less: accumulated depreciation and amortization		(1,024	)		(1,023	)
Property and equipment, net	$	7		$	8

Operating Leases
Operating lease right-of-use assets	$	1,636		$	657
Total operating lease right-of-use assets	$	1,636		$	657

Current portion of operating lease liabilities	$	589		$	420
Operating lease liabilities, less current portion		1,158			372
Total operating lease liabilities	$	1,747		$	792

Weighted Average Remaining Lease Term
Operating leases (in years)		3			3

Weighted Average Discount Rate
Operating leases		12.3	%		9.9	%

	*Operating*
Year Ending December 31,	*Leases*
2025 (excluding the three months ended March 31, 2025)	$	595
2026		607
2027		545
2028		365
2029		40
Thereafter		—
Total lease payments		2,152
Less: future interest expense		(405	)
Lease liabilities	$	1,747

ZEVRA THERAPEUTICS, INC. 10-Q